Ghana FDA approves first locally manufactured oncology drug
The Food and Drugs Authority has granted marketing authorisation to the first oncology medication manufactured entirely in Ghana.
The Food and Drugs Authority (FDA) has granted full marketing authorisation to the first oncology medication manufactured entirely in Ghana, a landmark for the country's pharmaceutical manufacturing sector.
FDA CEO Delese Mimi Darko said the drug — an oral chemotherapy agent for chronic myeloid leukaemia — had passed rigorous quality testing equivalent to international standards.
The manufacturer, Kinapharma Limited, invested over $12 million in upgrading its Accra facility to WHO GMP standards.
Related stories
Health
Senegal’s $7.1m Sickle Cell Drug Push Targets Six African Markets
Senegalese firm Teranga Pharma is expanding production of Drepaf, a locally manufactured generic hydroxyurea for sickle cell disease, backed by a $7.1 million project, and targeting six African markets with a goal of supplying sub-Saharan Africa by 2030
Health
20–30% of Katsina Diphtheria Patients May Die, State’s NMA Chair Warns
The NMA Katsina chair, Dr Mohammed Abubakar, says two to three of every 10 diphtheria patients admitted to Federal Teaching Hospital Katsina may die, as the state records over 1,000 suspected cases across 29 LGAs amid antitoxin shortages.
Health
Health Insurance Enrolment Rises but Coverage Gap Persists
Nigeria’s health insurance enrolment has climbed to 22.03 million by July 2026, a 35 per cent year-on-year rise, yet millions remain uncovered and exposed to high out-of-pocket costs, with structural barriers slowing the march to universal health coverage
Health
Diphtheria Outbreak Spreads to 29 Katsina LGAs as Kano Confirms Two More Deaths
Katsina State says suspected diphtheria cases have now spread to 29 of its 34 local government areas, with Funtua worst-hit, as neighbouring Kano confirms two fresh deaths in Rano LGA and the Federal Government deploys 500,000 vaccine doses to both states.
Comments (0)
Leave a comment
All comments are moderated before publishing. Your email is never published.